Unicycive
  • Home
  • Company
  • Therapeutic Focus
  • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
  • Investors
  • Resources
  • Careers
  • Contact

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Sep 06, 2022 7:00am EDT

Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 24, 2022 7:00am EDT

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022

Aug 15, 2022 6:03pm EDT

Unicycive Announces Second Quarter Financial Results and Provides Business Update

Jul 26, 2022 7:00am EDT

Unicycive Reports Key Findings from Independent Renal Dietitian Survey

Jul 20, 2022 7:11am EDT

Unicycive Reports Key Findings from Market Research with Nephrologists

Jul 18, 2022 7:00am EDT

Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets

Jun 06, 2022 8:00am EDT

Unicycive to Present at JMP Securities Life Sciences Conference

Jun 02, 2022 8:00am EDT

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

May 12, 2022 7:00am EDT

Unicycive Announces First Quarter Financial Results and Provides Business Update

Apr 14, 2022 7:10am EDT

Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases

  • arrow_back
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Legal Notices and Terms of Use
Privacy Policy
Ad and Cookie Policy
Contact Us >

Copyright © 2025 Unicycive

  • Twitter
  • LinkedIn
  • YouTube